Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Genetic susceptibility to distinct bladder cancer subphenotypes.

Guey LT, García-Closas M, Murta-Nascimento C, Lloreta J, Palencia L, Kogevinas M, Rothman N, Vellalta G, Calle ML, Marenne G, Tardón A, Carrato A, García-Closas R, Serra C, Silverman DT, Chanock S, Real FX, Malats N; EPICURO/Spanish Bladder Cancer Study investigators.

Eur Urol. 2010 Feb;57(2):283-92. doi: 10.1016/j.eururo.2009.08.001. Epub 2009 Aug 12.

2.

NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.

García-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Castaño-Vinyals G, Yeager M, Welch R, Chanock S, Chatterjee N, Wacholder S, Samanic C, Torà M, Fernández F, Real FX, Rothman N.

Lancet. 2005 Aug 20-26;366(9486):649-59.

3.

Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China.

Song DK, Xing DL, Zhang LR, Li ZX, Liu J, Qiao BP.

Cancer Detect Prev. 2009;32(5-6):416-23. doi: 10.1016/j.cdp.2009.02.003. Epub 2009 Mar 20.

PMID:
19303722
4.

Polymorphic deletions of the GSTT1 and GSTM1 genes and susceptibility to bladder cancer.

Salinas-Sánchez AS, Sánchez-Sánchez F, Donate-Moreno MJ, Rubio-del-Campo A, Gimenez-Bachs JM, Lorenzo-Romero JG, Serrano-Oviedo L, Escribano J.

BJU Int. 2011 Jun;107(11):1825-32. doi: 10.1111/j.1464-410X.2010.09683.x. Epub 2010 Oct 13.

5.
6.

Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk.

García-Closas M, Malats N, Real FX, Yeager M, Welch R, Silverman D, Kogevinas M, Dosemeci M, Figueroa J, Chatterjee N, Tardón A, Serra C, Carrato A, García-Closas R, Murta-Nascimento C, Rothman N, Chanock SJ.

PLoS Genet. 2007 Feb 23;3(2):e29. Epub 2007 Jan 4.

7.

Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.

Okkels H, Sigsgaard T, Wolf H, Autrup H.

Cancer Epidemiol Biomarkers Prev. 1997 Apr;6(4):225-31.

8.

Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility.

Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S.

Urol Oncol. 2013 Oct;31(7):1193-203. doi: 10.1016/j.urolonc.2011.11.027. Epub 2011 Dec 11.

PMID:
22154357
9.

GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study.

Matic M, Pekmezovic T, Djukic T, Mimic-Oka J, Dragicevic D, Krivic B, Suvakov S, Savic-Radojevic A, Pljesa-Ercegovac M, Tulic C, Coric V, Simic T.

Urol Oncol. 2013 Oct;31(7):1184-92. doi: 10.1016/j.urolonc.2011.08.005.

PMID:
24075358
10.

Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study.

Moore LE, Pfeiffer RM, Poscablo C, Real FX, Kogevinas M, Silverman D, García-Closas R, Chanock S, Tardón A, Serra C, Carrato A, Dosemeci M, García-Closas M, Esteller M, Fraga M, Rothman N, Malats N.

Lancet Oncol. 2008 Apr;9(4):359-66. doi: 10.1016/S1470-2045(08)70038-X. Epub 2008 Mar 12.

11.

GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis.

Moore LE, Baris DR, Figueroa JD, Garcia-Closas M, Karagas MR, Schwenn MR, Johnson AT, Lubin JH, Hein DW, Dagnall CL, Colt JS, Kida M, Jones MA, Schned AR, Cherala SS, Chanock SJ, Cantor KP, Silverman DT, Rothman N.

Carcinogenesis. 2011 Feb;32(2):182-9. doi: 10.1093/carcin/bgq223. Epub 2010 Oct 29.

12.

NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese.

Inatomi H, Katoh T, Kawamoto T, Matsumoto T.

Int J Urol. 1999 Sep;6(9):446-54. Erratum in: Int J Urol 1999 Nov;6(11):592.

13.

Comprehensive pathway-based interrogation of genetic variations in the nucleotide excision DNA repair pathway and risk of bladder cancer.

Xing J, Dinney CP, Shete S, Huang M, Hildebrandt MA, Chen Z, Gu J.

Cancer. 2012 Jan 1;118(1):205-15. doi: 10.1002/cncr.26224. Epub 2011 Jun 20.

14.

Genetic variation in the TP53 pathway and bladder cancer risk. a comprehensive analysis.

Pineda S, Milne RL, Calle ML, Rothman N, López de Maturana E, Herranz J, Kogevinas M, Chanock SJ, Tardón A, Márquez M, Guey LT, García-Closas M, Lloreta J, Baum E, González-Neira A, Carrato A, Navarro A, Silverman DT, Real FX, Malats N.

PLoS One. 2014 May 12;9(5):e89952. doi: 10.1371/journal.pone.0089952. eCollection 2014.

15.

Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk?

Murta-Nascimento C, Silverman DT, Kogevinas M, García-Closas M, Rothman N, Tardón A, García-Closas R, Serra C, Carrato A, Villanueva C, Dosemeci M, Real FX, Malats N.

Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1595-600.

16.

Differential association for N-acetyltransferase 2 genotype and phenotype with bladder cancer risk in Chinese population.

Quan L, Chattopadhyay K, Nelson HH, Chan KK, Xiang YB, Zhang W, Wang R, Gao YT, Yuan JM.

Oncotarget. 2016 Jun 28;7(26):40012-40024. doi: 10.18632/oncotarget.9475.

17.

Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer.

Yuan JM, Chan KK, Coetzee GA, Castelao JE, Watson MA, Bell DA, Wang R, Yu MC.

Carcinogenesis. 2008 Jul;29(7):1386-93. doi: 10.1093/carcin/bgn136. Epub 2008 Jun 9.

18.

NAT2 slow acetylation and bladder cancer in workers exposed to benzidine.

Carreón T, Ruder AM, Schulte PA, Hayes RB, Rothman N, Waters M, Grant DJ, Boissy R, Bell DA, Kadlubar FF, Hemstreet GP 3rd, Yin S, LeMasters GK.

Int J Cancer. 2006 Jan 1;118(1):161-8.

19.

Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumours.

Yates DR, Rouprêt M, Drouin SJ, Audouin M, Cancel-Tassin G, Comperat E, Bitker MO, Cussenot O.

World J Urol. 2013 Feb;31(1):53-9. doi: 10.1007/s00345-012-0954-6. Epub 2012 Sep 28.

PMID:
23053209
20.

Association Between N-acetyltransferase 2 Polymorphism and Bladder Cancer Risk: Results From Studies of the Past Decade and a Meta-Analysis.

Wu H, Wang X, Zhang L, Mo N, Lv Z.

Clin Genitourin Cancer. 2016 Apr;14(2):122-9. doi: 10.1016/j.clgc.2015.10.007. Epub 2015 Oct 26. Review.

PMID:
26585839

Supplemental Content

Support Center